[96a5a0]: / output / allTrials / logical / NCT00842348_logical.json

Download this file

764 lines (764 with data), 37.8 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
{
"info": {
"nct_id": "NCT00842348",
"official_title": "Open Label Extension Study of Lanreotide Autogel 120 mg in Patients With Non-functioning Entero-pancreatic Endocrine Tumour",
"inclusion_criteria": "1. Had provided written informed consent prior to any study-related procedures.\n2. Had been enrolled and treated in Study 2-55-52030-726 and either:\n\n * Was stable at 96 weeks of treatment (whatever the treatment received during the 2 years of participation, i.e. no code break at Week 96); or,\n * Had received at least one injection in Study 2-55-52030-726 and had disease progression, confirmed by central assessment, during the course of the study and code break showed placebo.\n3. Had a World Health Organisation (WHO) performance score lower than or equal to 2.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
"exclusion_criteria": "1. Had been enrolled and treated in the frame of the protocol and had disease progression during the study and the code break showed a treatment with lanreotide Autogel 120 mg.\n2. Had received any new treatment for the entero-pancreatic NET since the end of participation in the study.\n3. Were likely to require any additional concomitant treatment to lanreotide Autogel 120 mg for the entero-pancreatic NET.\n4. Had been treated with radionuclide at any time prior to study entry.\n5. Had a history of hypersensitivity to drugs with a similar chemical structure to lanreotide Autogel 120 mg.\n6. Were likely to require treatment during the study with drugs that were not permitted by the study protocol.\n7. Were at risk of pregnancy or lactation. Females of childbearing potential had to provide a negative pregnancy test at the start of study and had to be using oral, double barrier or injectable contraception. Non-childbearing potential was defined as postmenopause for at least 1 year, or surgical sterilisation or hysterectomy at least 3 months before the start of the study.\n8. Had any mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude.\n9. Had abnormal findings at Visit 1, any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might have jeopardised the patient's safety or decreased the chance of obtaining satisfactory data needed to achieve the objective(s) of the study.\n10. Previous enrolment in this study.",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"identified_line": {
"line": "1. Had provided written informed consent prior to any study-related procedures.",
"criterions": [
{
"exact_snippets": "provided written informed consent",
"criterion": "informed consent",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "provided written informed consent",
"criterion": "informed consent",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "2. Had been enrolled and treated in Study 2-55-52030-726 and either:",
"criterions": [
{
"exact_snippets": "Had been enrolled and treated in Study 2-55-52030-726",
"criterion": "enrollment and treatment in Study 2-55-52030-726",
"requirement": {
"requirement_type": "status",
"expected_value": true
}
}
]
},
"logical_structure": {
"condition": {
"exact_snippets": "Had been enrolled and treated in Study 2-55-52030-726",
"criterion": "enrollment and treatment in Study 2-55-52030-726",
"requirement": {
"requirement_type": "status",
"expected_value": true
}
},
"then_criteria": null,
"else_criteria": null
}
},
{
"identified_line": {
"line": "* Was stable at 96 weeks of treatment (whatever the treatment received during the 2 years of participation, i.e. no code break at Week 96); or,",
"criterions": [
{
"exact_snippets": "stable at 96 weeks of treatment",
"criterion": "stability at 96 weeks of treatment",
"requirement": {
"requirement_type": "status",
"expected_value": "stable"
}
},
{
"exact_snippets": "no code break at Week 96",
"criterion": "code break at Week 96",
"requirement": {
"requirement_type": "occurrence",
"expected_value": false
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "stable at 96 weeks of treatment",
"criterion": "stability at 96 weeks of treatment",
"requirement": {
"requirement_type": "status",
"expected_value": "stable"
}
},
{
"exact_snippets": "no code break at Week 96",
"criterion": "code break at Week 96",
"requirement": {
"requirement_type": "occurrence",
"expected_value": false
}
}
]
}
]
}
},
{
"identified_line": {
"line": "* Had received at least one injection in Study 2-55-52030-726 and had disease progression, confirmed by central assessment, during the course of the study and code break showed placebo.",
"criterions": [
{
"exact_snippets": "Had received at least one injection in Study 2-55-52030-726",
"criterion": "injection in Study 2-55-52030-726",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "had disease progression, confirmed by central assessment, during the course of the study",
"criterion": "disease progression",
"requirement": {
"requirement_type": "confirmation",
"expected_value": "central assessment"
}
},
{
"exact_snippets": "code break showed placebo",
"criterion": "code break result",
"requirement": {
"requirement_type": "result",
"expected_value": "placebo"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Had received at least one injection in Study 2-55-52030-726",
"criterion": "injection in Study 2-55-52030-726",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "had disease progression, confirmed by central assessment, during the course of the study",
"criterion": "disease progression",
"requirement": {
"requirement_type": "confirmation",
"expected_value": "central assessment"
}
}
]
},
{
"exact_snippets": "code break showed placebo",
"criterion": "code break result",
"requirement": {
"requirement_type": "result",
"expected_value": "placebo"
}
}
]
}
},
{
"identified_line": {
"line": "3. Had a World Health Organisation (WHO) performance score lower than or equal to 2.",
"criterions": [
{
"exact_snippets": "World Health Organisation (WHO) performance score lower than or equal to 2",
"criterion": "WHO performance score",
"requirement": {
"requirement_type": "score",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "N/A"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "World Health Organisation (WHO) performance score lower than or equal to 2",
"criterion": "WHO performance score",
"requirement": {
"requirement_type": "score",
"expected_value": {
"operator": "<=",
"value": 2,
"unit": "N/A"
}
}
}
]
}
},
{
"identified_line": {
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirement": {
"requirement_type": "status",
"expected_value": "healthy"
}
}
]
}
},
{
"identified_line": {
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirement": {
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
}
]
}
}
],
"exclusion_lines": [
{
"identified_line": {
"line": "1. Had been enrolled and treated in the frame of the protocol and had disease progression during the study and the code break showed a treatment with lanreotide Autogel 120 mg.",
"criterions": [
{
"exact_snippets": "Had been enrolled and treated in the frame of the protocol",
"criterion": "enrollment and treatment in the protocol",
"requirement": {
"requirement_type": "status",
"expected_value": "completed"
}
},
{
"exact_snippets": "had disease progression during the study",
"criterion": "disease progression",
"requirement": {
"requirement_type": "status",
"expected_value": true
}
},
{
"exact_snippets": "the code break showed a treatment with lanreotide Autogel 120 mg",
"criterion": "treatment with lanreotide Autogel",
"requirement": {
"requirement_type": "dosage",
"expected_value": "120 mg"
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Had been enrolled and treated in the frame of the protocol",
"criterion": "enrollment and treatment in the protocol",
"requirement": {
"requirement_type": "status",
"expected_value": "completed"
}
},
{
"exact_snippets": "had disease progression during the study",
"criterion": "disease progression",
"requirement": {
"requirement_type": "status",
"expected_value": true
}
}
]
},
{
"exact_snippets": "the code break showed a treatment with lanreotide Autogel 120 mg",
"criterion": "treatment with lanreotide Autogel",
"requirement": {
"requirement_type": "dosage",
"expected_value": "120 mg"
}
}
]
}
},
{
"identified_line": {
"line": "2. Had received any new treatment for the entero-pancreatic NET since the end of participation in the study.",
"criterions": [
{
"exact_snippets": "Had received any new treatment for the entero-pancreatic NET",
"criterion": "new treatment for entero-pancreatic NET",
"requirement": {
"requirement_type": "receipt",
"expected_value": false
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Had received any new treatment for the entero-pancreatic NET",
"criterion": "new treatment for entero-pancreatic NET",
"requirement": {
"requirement_type": "receipt",
"expected_value": false
}
}
}
},
{
"identified_line": {
"line": "3. Were likely to require any additional concomitant treatment to lanreotide Autogel 120 mg for the entero-pancreatic NET.",
"criterions": [
{
"exact_snippets": "likely to require any additional concomitant treatment to lanreotide Autogel 120 mg",
"criterion": "requirement for additional concomitant treatment",
"requirement": {
"requirement_type": "necessity",
"expected_value": false
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "likely to require any additional concomitant treatment to lanreotide Autogel 120 mg",
"criterion": "requirement for additional concomitant treatment",
"requirement": {
"requirement_type": "necessity",
"expected_value": false
}
}
}
},
{
"identified_line": {
"line": "4. Had been treated with radionuclide at any time prior to study entry.",
"criterions": [
{
"exact_snippets": "Had been treated with radionuclide at any time prior to study entry.",
"criterion": "radionuclide treatment",
"requirement": {
"requirement_type": "prior treatment",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "Had been treated with radionuclide at any time prior to study entry.",
"criterion": "radionuclide treatment",
"requirement": {
"requirement_type": "prior treatment",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "5. Had a history of hypersensitivity to drugs with a similar chemical structure to lanreotide Autogel 120 mg.",
"criterions": [
{
"exact_snippets": "history of hypersensitivity to drugs with a similar chemical structure to lanreotide Autogel 120 mg",
"criterion": "hypersensitivity to drugs with a similar chemical structure to lanreotide Autogel",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"exact_snippets": "history of hypersensitivity to drugs with a similar chemical structure to lanreotide Autogel 120 mg",
"criterion": "hypersensitivity to drugs with a similar chemical structure to lanreotide Autogel",
"requirement": {
"requirement_type": "history",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "6. Were likely to require treatment during the study with drugs that were not permitted by the study protocol.",
"criterions": [
{
"exact_snippets": "require treatment during the study with drugs that were not permitted by the study protocol",
"criterion": "requirement for non-permitted drugs",
"requirement": {
"requirement_type": "likelihood",
"expected_value": true
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "require treatment during the study with drugs that were not permitted by the study protocol",
"criterion": "requirement for non-permitted drugs",
"requirement": {
"requirement_type": "likelihood",
"expected_value": true
}
}
}
},
{
"identified_line": {
"line": "7. Were at risk of pregnancy or lactation. Females of childbearing potential had to provide a negative pregnancy test at the start of study and had to be using oral, double barrier or injectable contraception. Non-childbearing potential was defined as postmenopause for at least 1 year, or surgical sterilisation or hysterectomy at least 3 months before the start of the study.",
"criterions": [
{
"exact_snippets": "at risk of pregnancy",
"criterion": "risk of pregnancy",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "lactation",
"criterion": "lactation",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
},
{
"exact_snippets": "Females of childbearing potential had to provide a negative pregnancy test",
"criterion": "pregnancy test",
"requirement": {
"requirement_type": "result",
"expected_value": "negative"
}
},
{
"exact_snippets": "Females of childbearing potential ... had to be using oral, double barrier or injectable contraception",
"criterion": "contraception use",
"requirement": {
"requirement_type": "method",
"expected_value": [
"oral",
"double barrier",
"injectable"
]
}
},
{
"exact_snippets": "Non-childbearing potential was defined as postmenopause for at least 1 year",
"criterion": "postmenopause",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "year"
}
}
},
{
"exact_snippets": "Non-childbearing potential was defined as ... surgical sterilisation or hysterectomy at least 3 months before the start of the study",
"criterion": "surgical sterilisation or hysterectomy",
"requirement": {
"requirement_type": "time since procedure",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "months"
}
}
}
]
},
"logical_structure": {
"and_criteria": [
{
"or_criteria": [
{
"and_criteria": [
{
"not_criteria": {
"exact_snippets": "at risk of pregnancy",
"criterion": "risk of pregnancy",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
},
{
"not_criteria": {
"exact_snippets": "lactation",
"criterion": "lactation",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
}
]
}
]
},
{
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Females of childbearing potential had to provide a negative pregnancy test",
"criterion": "pregnancy test",
"requirement": {
"requirement_type": "result",
"expected_value": "negative"
}
},
{
"exact_snippets": "Females of childbearing potential ... had to be using oral, double barrier or injectable contraception",
"criterion": "contraception use",
"requirement": {
"requirement_type": "method",
"expected_value": [
"oral",
"double barrier",
"injectable"
]
}
}
]
},
{
"exact_snippets": "Non-childbearing potential was defined as postmenopause for at least 1 year",
"criterion": "postmenopause",
"requirement": {
"requirement_type": "duration",
"expected_value": {
"operator": ">=",
"value": 1,
"unit": "year"
}
}
},
{
"exact_snippets": "Non-childbearing potential was defined as ... surgical sterilisation or hysterectomy at least 3 months before the start of the study",
"criterion": "surgical sterilisation or hysterectomy",
"requirement": {
"requirement_type": "time since procedure",
"expected_value": {
"operator": ">=",
"value": 3,
"unit": "months"
}
}
}
]
}
]
}
},
{
"identified_line": {
"line": "8. Had any mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study, and/or evidence of an uncooperative attitude.",
"criterions": [
{
"exact_snippets": "Had any mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study",
"criterion": "mental condition",
"requirement": {
"requirement_type": "impact on understanding",
"expected_value": "unable to understand the nature, scope and possible consequences of the study"
}
},
{
"exact_snippets": "evidence of an uncooperative attitude",
"criterion": "uncooperative attitude",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "Had any mental condition rendering the patient unable to understand the nature, scope and possible consequences of the study",
"criterion": "mental condition",
"requirement": {
"requirement_type": "impact on understanding",
"expected_value": "unable to understand the nature, scope and possible consequences of the study"
}
},
{
"exact_snippets": "evidence of an uncooperative attitude",
"criterion": "uncooperative attitude",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
},
{
"exact_snippets": "evidence of an uncooperative attitude",
"criterion": "uncooperative attitude",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "9. Had abnormal findings at Visit 1, any other medical condition(s) or laboratory findings that, in the opinion of the investigator, might have jeopardised the patient's safety or decreased the chance of obtaining satisfactory data needed to achieve the objective(s) of the study.",
"criterions": [
{
"exact_snippets": "abnormal findings at Visit 1",
"criterion": "abnormal findings at Visit 1",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "any other medical condition(s)",
"criterion": "other medical conditions",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "laboratory findings that, in the opinion of the investigator, might have jeopardised the patient's safety or decreased the chance of obtaining satisfactory data",
"criterion": "laboratory findings",
"requirement": {
"requirement_type": "impact on safety or data quality",
"expected_value": "jeopardise safety or decrease data quality"
}
}
]
},
"logical_structure": {
"or_criteria": [
{
"and_criteria": [
{
"exact_snippets": "abnormal findings at Visit 1",
"criterion": "abnormal findings at Visit 1",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
},
{
"exact_snippets": "laboratory findings that, in the opinion of the investigator, might have jeopardised the patient's safety or decreased the chance of obtaining satisfactory data",
"criterion": "laboratory findings",
"requirement": {
"requirement_type": "impact on safety or data quality",
"expected_value": "jeopardise safety or decrease data quality"
}
}
]
},
{
"exact_snippets": "any other medical condition(s)",
"criterion": "other medical conditions",
"requirement": {
"requirement_type": "presence",
"expected_value": true
}
}
]
}
},
{
"identified_line": {
"line": "10. Previous enrolment in this study.",
"criterions": [
{
"exact_snippets": "Previous enrolment in this study.",
"criterion": "previous enrolment",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
]
},
"logical_structure": {
"not_criteria": {
"exact_snippets": "Previous enrolment in this study.",
"criterion": "previous enrolment",
"requirement": {
"requirement_type": "presence",
"expected_value": false
}
}
}
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}